Rhumbline Advisers Has $258.39 Million Stock Holdings in Gilead Sciences, Inc. $GILD

Rhumbline Advisers cut its holdings in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 0.7% during the 3rd quarter, Holdings Channel reports. The institutional investor owned 2,327,866 shares of the biopharmaceutical company’s stock after selling 15,602 shares during the quarter. Rhumbline Advisers’ holdings in Gilead Sciences were worth $258,393,000 at the end of the most recent quarter.

Other large investors have also recently bought and sold shares of the company. Stratos Wealth Partners LTD. increased its stake in shares of Gilead Sciences by 17.4% in the 3rd quarter. Stratos Wealth Partners LTD. now owns 98,455 shares of the biopharmaceutical company’s stock valued at $10,929,000 after acquiring an additional 14,577 shares in the last quarter. Stratos Investment Management LLC increased its stake in shares of Gilead Sciences by 5.5% during the 3rd quarter. Stratos Investment Management LLC now owns 4,722 shares of the biopharmaceutical company’s stock worth $524,000 after purchasing an additional 246 shares during the last quarter. MQS Management LLC purchased a new stake in Gilead Sciences during the third quarter valued at about $366,000. SVB Wealth LLC raised its stake in shares of Gilead Sciences by 5.1% during the 3rd quarter. SVB Wealth LLC now owns 37,085 shares of the biopharmaceutical company’s stock valued at $4,116,000 after purchasing an additional 1,789 shares during the period. Finally, Midwest Trust Co boosted its holdings in Gilead Sciences by 1.7% in the 3rd quarter. Midwest Trust Co now owns 9,113 shares of the biopharmaceutical company’s stock valued at $1,012,000 after purchasing an additional 148 shares during the period. 83.67% of the stock is currently owned by institutional investors and hedge funds.

Gilead Sciences News Roundup

Here are the key news stories impacting Gilead Sciences this week:

• Positive Sentiment: Q4 results beat: Gilead reported EPS of $1.86 and revenue of ~$7.9B, topping consensus and driven by strong HIV and liver‑disease sales. Gilead Sciences Inc (GILD) Q4 2025 Earnings Call Highlights: Strong HIV Sales Drive Growth …
• Positive Sentiment: Dividend raised: Board approved a 3.8% increase to $0.82 quarterly ($0.82 payable Mar 30; ex‑div Mar 13), supporting income investors (yield ~2.2%). Gilead Sciences Announces 3.8-Percent Increase in First Quarter 2026 Dividend
• Positive Sentiment: Pipeline and launches: Management highlighted Yeztugo launch momentum and possible approvals later this year (two cancer therapies plus an additional HIV option), which could drive future growth. Gilead Sciences Profit Rises on Growth of Liver Disease, HIV Products
• Neutral Sentiment: Full Q4 call transcript now available for detail on revenue mix and margin drivers — useful for investors digging into product‑level trends. Gilead Sciences, Inc. (GILD) Q4 2025 Earnings Call Transcript
• Neutral Sentiment: Analysts’ metric review: Several outlets note Gilead beat top‑ and bottom‑line estimates but some year‑over‑year metrics are mixed — monitor product mix and FX effects in the slides. Gilead (GILD) Q4 Earnings: How Key Metrics Compare to Wall Street Estimates
• Negative Sentiment: Guidance disappointed: FY‑2026 EPS guidance of $8.45–8.85 and revenue $29.6–30.0B sit at or below consensus (EPS ~8.69; revenue ~30.1B), prompting the after‑hours selloff. Expect near‑term pressure until guidance proves conservative or growth catalysts materialize. Gilead 2026 outlook short of Wall Street view, shares dip

Gilead Sciences Trading Down 2.9%

Shares of GILD stock opened at $147.23 on Wednesday. The company has a current ratio of 1.45, a quick ratio of 1.31 and a debt-to-equity ratio of 1.03. Gilead Sciences, Inc. has a 12-month low of $93.37 and a 12-month high of $153.13. The stock’s 50-day moving average price is $128.39 and its 200-day moving average price is $121.53. The stock has a market capitalization of $182.67 billion, a price-to-earnings ratio of 22.83, a price-to-earnings-growth ratio of 0.80 and a beta of 0.36.

Gilead Sciences (NASDAQ:GILD) last issued its quarterly earnings data on Tuesday, February 10th. The biopharmaceutical company reported $1.86 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.83 by $0.03. The business had revenue of $7.93 billion for the quarter, compared to the consensus estimate of $7.68 billion. Gilead Sciences had a return on equity of 51.86% and a net margin of 27.88%.The company’s quarterly revenue was up 4.7% compared to the same quarter last year. During the same period in the prior year, the business posted $1.90 earnings per share. Gilead Sciences has set its FY 2026 guidance at 8.450-8.850 EPS. Equities research analysts predict that Gilead Sciences, Inc. will post 7.95 EPS for the current fiscal year.

Gilead Sciences Increases Dividend

The company also recently declared a quarterly dividend, which will be paid on Monday, March 30th. Investors of record on Friday, March 13th will be issued a dividend of $0.82 per share. This represents a $3.28 annualized dividend and a yield of 2.2%. The ex-dividend date is Friday, March 13th. This is a positive change from Gilead Sciences’s previous quarterly dividend of $0.79. Gilead Sciences’s payout ratio is currently 48.99%.

Insider Transactions at Gilead Sciences

In related news, Director Jeffrey Bluestone sold 5,000 shares of the firm’s stock in a transaction dated Tuesday, January 20th. The shares were sold at an average price of $123.50, for a total value of $617,500.00. Following the transaction, the director owned 8,920 shares of the company’s stock, valued at $1,101,620. This trade represents a 35.92% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, insider Johanna Mercier sold 3,000 shares of Gilead Sciences stock in a transaction that occurred on Thursday, January 15th. The shares were sold at an average price of $124.31, for a total transaction of $372,930.00. Following the sale, the insider directly owned 103,221 shares of the company’s stock, valued at $12,831,402.51. This represents a 2.82% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last 90 days, insiders sold 319,391 shares of company stock valued at $44,141,101. Company insiders own 0.27% of the company’s stock.

Wall Street Analyst Weigh In

A number of research firms recently weighed in on GILD. Wall Street Zen downgraded Gilead Sciences from a “strong-buy” rating to a “buy” rating in a research report on Friday, January 23rd. Cantor Fitzgerald reiterated an “overweight” rating and set a $135.00 target price on shares of Gilead Sciences in a report on Friday, October 31st. Scotiabank initiated coverage on shares of Gilead Sciences in a research report on Thursday, November 13th. They set a “sector outperform” rating and a $140.00 price target for the company. Leerink Partners upped their price objective on Gilead Sciences from $114.00 to $146.00 and gave the company an “outperform” rating in a research report on Friday, January 30th. Finally, Wolfe Research lifted their target price on Gilead Sciences from $150.00 to $155.00 and gave the company an “outperform” rating in a research report on Wednesday, January 28th. One investment analyst has rated the stock with a Strong Buy rating, twenty-four have assigned a Buy rating and three have issued a Hold rating to the company’s stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $136.73.

Gilead Sciences Company Profile

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.